International Multicenter Validation of GES Score for HCC Risk Stratification in Chronic Hepatitis C Patients

Autor: MA Hashim, Nabiel Mikhail, Gamal Shiha, M Hassan, Mohammed Eslam, S.K. Sarin, Kentaro Matsuura, Manish Kumar, L Ni, AM Ahumada, Shigeru Mikami, Reham Soliman, SA Lopez, J Zou, Hidenori Toyoda, Suri, Haruki Uojima, Atsushi Hiraoka, Hiroshi Abe, Akito Nozaki, PK Jalal, Kunihiko Tsuji, Masanori Atsukawa, K Takaguchi, Anu Osinusi, Fabrice Carrat, Imam Waked, Toru Ishikawa, Tomohiro Watanabe, Ganne-Carrié Nathalie, R Bañares, Nasser Mousa, J Azzi
Přispěvatelé: Mansoura University [Egypt], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de santé publique [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpitaux Paris Seine-Saint-Denis [Bobigny], Kitasato University, Yokohama National University, Kagawa University [Japan], Ehime University [Matsuyama, Japon], Nippon Medical School [Tokyo, Japon], Nagoya City University [Nagoya, Japan], St. Marianna University School of Medicine [Kanagawa, Japan], Gilead Sciences, Inc. [Foster City, CA, USA], Institute of Liver and Biliary Sciences [New Delhi], Baylor College of Medicine (BCM), Baylor University, Hospital General Universitario 'Gregorio Marañón' [Madrid], Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Liver Unit, Clínica Universitaria, CIBER-EHD, Westmead Hospital [Sydney], The University of Sydney, HAL-SU, Gestionnaire
Rok vydání: 2021
Předmět:
MESH: Antiviral Agents
History
medicine.medical_specialty
Carcinoma
Hepatocellular
Polymers and Plastics
Hepatitis C virus
AFP
HCV genotypes
Hepacivirus
MESH: Risk Assessment
medicine.disease_cause
Antiviral Agents
Risk Assessment
Industrial and Manufacturing Engineering
law.invention
Chronic hepatitis
Randomized controlled trial
MESH: Liver Neoplasms
MESH: Risk Factors
Risk Factors
law
Virology
Internal medicine
Humans
Medicine
MESH: Hepacivirus
Business and International Management
MESH: Carcinoma
Hepatocellular
HCC risk scores
Survival analysis
Retrospective Studies
MESH: Humans
Hepatology
business.industry
Liver Neoplasms
MESH: Retrospective Studies
Hepatitis C
Chronic
medicine.disease
MESH: Hepatitis C
Chronic
CHC
Infectious Diseases
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Hepatocellular carcinoma
Risk stratification
Cohort
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
business
Zdroj: Journal of Viral Hepatitis
Journal of Viral Hepatitis, Wiley-Blackwell, 2022, 29 (9), pp.807-816. ⟨10.1111/jvh.13717⟩
ISSN: 1556-5068
1352-0504
1365-2893
Popis: Background and Aims: We have recently demonstrated the ability of a simple predictive model (GES) score to determine the risk of hepatocellular carcinoma (HCC) after using direct-acting antivirals. However, our results were restricted to Egyptian patients with hepatitis C virus (HCV) genotype 4. Therefore, we studied a large, independent cohort of multiethnic populations through our international collaborative activity. Methods: Depending on their GES scores, patients are stratified into low risk (≤ 6/12.5), intermediate risk (> 6–7.5/12.5), and high risk (> 7.5/12.5) for HCC. A total of 12038 patients with chronic HCV were analyzed in this study, of whom 11202 were recruited from 54 centers in France, Japan, India, the U.S., and Spain, and the remaining 836 were selected from the Gilead-sponsored randomized controlled trial conducted across the U.S., Europe, Canada, and Australia. Descriptive statistics and survival analysis were performed using Kaplan–Meier and log-rank tests. The performance of the GES score was evaluated using Harrell’s C-index (HCI). Results : The GES score proved successful at stratifying all patients into 3 risk groups, namely low-risk, intermediate-risk, and high-risk. It also displayed significant predictive value for HCC development in all participants (P < 0 .0001), with HCI ranging from 0.55 to 0.76 among all cohorts after adjusting for HCV genotypes and patient ethnicities. Conclusion: The GES score can be used to stratify HCV patients into 3 categories of risk for HCC, namely low-risk, intermediate-risk, and high-risk, irrespective of their ethnicities or HCV genotypes. This international multicenter validation may allow the use of GES score in individualized HCC risk-based surveillance programs. Funding: None to declare. Declaration of Interest: None to declare. Ethical Approval: The protocol was approved by the Institutional Research Board of each participating center, as per local regulations
Databáze: OpenAIRE
Externí odkaz: